6don MSN
Easy-to-use tool can identify high- and low-risk metastatic prostate cancer patients earlier
A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...
The LynxDx leadership team. In the front row (from left to right) are: Spencer Heaton, Chief Medical and Commercial Officer; Steve Riggs, President; and Jeff Crays, Chief Technology Officer. In the ...
CENTENNIAL, Colo.-Nationally, prostate cancer is the second most common major cancer among men, and according to the North Dakota Statewide Cancer Registry, it was the most commonly occurring cancer ...
The US FDA has granted De Novo marketing authorization for ArteraAI Prostate (Artera, Los Altos, California), a novel artificial intelligence (AI)-powered risk-stratification tool for patients with ...
A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret ...
Hosted on MSN
A True Game-Changer in Prostate Cancer: A Simple Genomic Test Can Tell Us Who Needs Hormone Therapy And Who Doesn’t
If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback